Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Common Equity: 2020-2024

Historic Common Equity for Molecular Partners Ag (MOLN) over the last 5 years, with Dec 2024 value amounting to $160,998.

  • Molecular Partners Ag's Common Equity fell 25.45% to $119,418 in Q3 2025 from the same period last year, while for Sep 2025 it was $119,418, marking a year-over-year decrease of 25.45%. This contributed to the annual value of $160,998 for FY2024, which is 18.04% down from last year.
  • Latest data reveals that Molecular Partners Ag reported Common Equity of $160,998 as of FY2024, which was down 18.04% from $196,444 recorded in FY2023.
  • Over the past 5 years, Molecular Partners Ag's Common Equity peaked at $118.6 million during FY2020, and registered a low of $116,355 during FY2021.
  • Moreover, its 3-year median value for Common Equity was $196,444 (2023), whereas its average is $200,516.
  • In the last 5 years, Molecular Partners Ag's Common Equity plummeted by 99.90% in 2021 and then soared by 109.80% in 2022.
  • Molecular Partners Ag's Common Equity (Yearly) stood at $118.6 million in 2020, then slumped by 99.90% to $116,355 in 2021, then soared by 109.80% to $244,107 in 2022, then declined by 19.53% to $196,444 in 2023, then decreased by 18.04% to $160,998 in 2024.